

Fund Fact Sheet
Fund Overview

Base Currency for Fund	USD
Total Net Assets (USD)	1.84 billion
Fund Inception Date	03.04.2000
Number of Issuers	84
Benchmark	NASDAQ Biotechnology Index
Investment Style	Sector
Morningstar Category™	Sector Equity Biotechnology

Summary of Investment Objective

The Fund aims to achieve capital appreciation by investing principally in equity securities of biotechnology companies and discovery research firms mainly located in the US.

Fund Management


Evan McCulloch, CFA: United States
Wendy Lam, PhD: United States
Steve Kornfeld, CFA: United States

Ratings - A (acc) USD

Overall Morningstar Rating™: ★★ ★

Asset Allocation

Equity	92.83%
Cash & Cash Equivalents	7.17%

Performance
Performance over 5 Years in EUR (%)

Discrete Annual Performance in EUR (%)

	04/18	04/17	04/16	04/15	04/14
	04/19	04/18	04/17	04/16	04/15
A (acc) USD	4.76	-9.37	23.98	-25.24	80.52
A (acc) EUR-H1	-5.57	N/A	N/A	N/A	N/A
Benchmark in EUR	10.60	-5.76	16.72	-21.43	80.22

Performance in EUR (%)

	Cumulative				Annualised		
	1 Yr	3 Yrs	5 Yrs	10 Yrs	3 Yrs	5 Yrs	10 Yrs
A (acc) USD	4.76	17.71	58.85	372.14	5.59	9.70	16.79
A (acc) EUR-H1	-5.57	N/A	N/A	N/A	N/A	N/A	N/A
Benchmark in EUR	10.60	21.66	72.27	491.41	6.76	11.49	19.45

Past performance is not an indicator or a guarantee of future performance. The value of shares in the fund and income received from it can go down as well as up, and investors may not get back the full amount invested. All performance data shown is in the currency stated, include reinvested dividends and are net of management fees. Sales charges and other commissions, taxes and other relevant costs paid by the investor are not included in the calculations. Performance may also be affected by currency fluctuations. Currency fluctuations may affect the value of overseas investments. The fund offers other share classes subject to different fees and expenses, which will affect their performance. Please see the prospectus for details. Up to date performance figures can be found on our local website.

References to indices are made for comparative purposes only and are provided to represent the investment environment existing during the time periods shown. When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates may be used between the portfolio and its benchmark.

Top Ten Holdings (% of Total)

Issuer Name	% of Total
ALEXION PHARMACEUTICALS INC	6.78
VERTEX PHARMACEUTICALS INC	5.01
ARRAY BIOPHARMA INC	4.97
ILLUMINA INC	4.81
BIOGEN INC	3.86
GW PHARMACEUTICALS PLC	3.68
REGENERON PHARMACEUTICALS INC	3.60
GILEAD SCIENCES INC	3.40
BIOMARIN PHARMACEUTICAL INC	3.23
AMGEN INC	3.12

Fund Measures

P/E to Growth	1.37x
Historical 3 Yr Sales Growth	55.83%
Estimated 3-5 Yr EPS Growth	27.71%
Price to Earnings (12-mo Forward)	14.85x
Standard Deviation (5 Yrs, USD)	23.85%

Share Class Information

Share Class	Incept Date	NAV	TER (%)	Fees		Dividends			Fund Identifiers	
				Max. Sales Charge (%)	Max. Annual Charge (%)	Frequency	Last Paid Date	Last Paid Amount	Bloomberg ID	ISIN
A (acc) USD	03.04.2000	USD 29.84	1.83	5.75	1.50	N/A	N/A	N/A	TEMBDAI LX	LU0109394709
A (acc) EUR-H1	06.04.2018	EUR 9.67	1.82	5.75	1.50	N/A	N/A	N/A	FTBAEH1 LX	LU1803069274

Composition of Fund

Market Capitalisation Breakdown in USD	% of Equity
<2.0 Billion	26.02
2.0-5.0 Billion	23.20
5.0-10.0 Billion	13.29
10.0-25.0 Billion	4.18
25.0-50.0 Billion	25.92
>50.0 Billion	7.03
N/A	0.36

What are the Key Risks?

The value of shares in the Fund and income received from it can go down as well as up and investors may not get back the full amount invested.

Performance may also be affected by currency fluctuations. Currency fluctuations may affect the value of overseas investments.

The Fund invests mainly in equity securities of biotechnology companies. Such securities have historically been subject to significant price movements that may occur suddenly due to market, sector or company-specific factors. As a result, the performance of the Fund can fluctuate significantly over relatively short time periods.

The Fund may distribute income gross of expenses. Whilst this might allow more income to be distributed, it may also have the effect of reducing capital.

Other significant risks include: liquidity risk.

For full details of all of the risks applicable to this Fund, please refer to the "Risk Considerations" section of the Fund in the current prospectus of Franklin Templeton Investment Funds.

Important Information

Issued by Franklin Templeton International Services, S.à r.l. Franklin Templeton Investment Funds (the "Fund") is a Luxembourg registered SICAV. Source for data and information provided by Franklin Templeton Investments, as of the date of this document, unless otherwise noted. This document does not constitute legal or tax advice nor investment advice or an offer for shares of the Fund. Subscriptions to shares of the Fund can only be made on the basis of the current prospectus and where available, the relevant Key Investor Information Document, accompanied by the latest available audited annual report and semi-annual report accessible on our website at www.franklintempleton.lu or which can be obtained, free of charge, from Franklin Templeton International Services, S.à r.l. - Supervised by the Commission de Surveillance du Secteur Financier - 8A, rue Albert Borschette, L-1246 Luxembourg. The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. No shares of the Fund may be directly or indirectly offered or sold to residents of the United States of America. Shares of the Fund are not available for distribution in all jurisdictions and prospective investors should confirm availability with their local Franklin Templeton Investments representative before making any plans to invest. An investment in the Fund entails risks, which are described in the Fund's prospectus and where available, in the relevant Key Investor Information Document. Special risks may be associated with a Fund's investment in certain types of securities, asset classes, sectors, markets, currencies or countries and in the Fund's possible use of derivatives. These risks are more fully described in the Fund's prospectus and where available, in the relevant Key Investor Information Document and should be read closely before investing. Information is historical and may not reflect current or future portfolio characteristics. All portfolio holdings are subject to change. References to particular industries, sectors or companies are for general information and are not necessarily indicative of a fund's holding at any one time.

Benchmark related data provided by FactSet, as of the date of this document, unless otherwise noted.

Please consult your financial advisor before deciding to invest.

Fund Management: CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

Ratings: © Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Top Ten Holdings: These securities do not represent all of the securities purchased, sold or recommended for clients, and the reader should not assume that investment in the securities listed was or will be profitable. The portfolio manager for the Fund reserves the right to withhold release of information with respect to holdings that would otherwise be included in the top holdings list.